Cibc World Market Inc. Boosts Stake in Invitae Co. (NYSE:NVTA)
Cibc World Market Inc. Boosts Stake in Invitae Co. (NYSE:NVTA)
Cibc World Market Inc. lifted its stake in Invitae Co. (NYSE:NVTA – Get Rating) by 249.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,571 shares of the medical research company's stock after purchasing an additional 133,945 shares during the period. Cibc World Market Inc. owned 0.08% of Invitae worth $458,000 at the end of the most recent reporting period.
根据加拿大帝国商业银行提交给美国证券交易委员会(美国证券交易委员会)的最新文件,加拿大帝国商业银行在第二季度增持了Invitae Co.的股份249.8%。该机构投资者持有这家医学研究公司187,571股股票,在此期间又购买了133,945股。截至最近一次报告期结束时,加拿大帝国商业银行世界市场公司拥有Invitae 0.08%的股份,价值458,000美元。
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Alyeska Investment Group L.P. bought a new position in Invitae in the 1st quarter worth $8,369,000. Renaissance Technologies LLC bought a new position in Invitae in the 1st quarter worth $8,279,000. State of Michigan Retirement System boosted its holdings in Invitae by 1,190.3% in the 2nd quarter. State of Michigan Retirement System now owns 1,095,950 shares of the medical research company's stock worth $2,674,000 after buying an additional 1,011,011 shares during the period. ARK Investment Management LLC boosted its holdings in Invitae by 3.6% in the 2nd quarter. ARK Investment Management LLC now owns 28,668,950 shares of the medical research company's stock worth $105,215,000 after buying an additional 986,724 shares during the period. Finally, Walleye Capital LLC boosted its holdings in Invitae by 695.9% in the 2nd quarter. Walleye Capital LLC now owns 708,886 shares of the medical research company's stock worth $1,730,000 after buying an additional 619,822 shares during the period. 88.27% of the stock is currently owned by hedge funds and other institutional investors.
其他几家对冲基金和其他机构投资者最近也调整了对该股的持有量。Alyeska Investment Group L.P.在第一季度购买了Invitae的一个新头寸,价值8,369,000美元。复兴科技有限责任公司在第一季度购买了Invitae的一个新头寸,价值8,279,000美元。密歇根州退休制度在第二季度将其在Invitae的持有量增加了1190.3%。密歇根州退休系统现在拥有1,095,950股这家医学研究公司的股票,价值2,674,000美元,在此期间又购买了1,011,011股。方舟投资管理有限责任公司在第二季度增持了3.6%的Invitae股份。方舟投资管理公司现在拥有28,668,950股这家医疗研究公司的股票,价值105,215,000美元,在此期间又购买了986,724股。最后,Walleye Capital LLC在第二季度将其在Invitae的持股增加了695.9%。Walleye Capital LLC现在持有这家医学研究公司708,886股股票,价值1,730,000美元,在此期间又购买了619,822股。88.27%的股票目前由对冲基金和其他机构投资者持有。
Invitae Price Performance
Invitae性价比
Shares of NYSE NVTA opened at $2.57 on Wednesday. The firm's 50-day moving average price is $2.61 and its 200-day moving average price is $2.93. The company has a debt-to-equity ratio of 10.03, a quick ratio of 6.18 and a current ratio of 6.44. Invitae Co. has a 12-month low of $1.83 and a 12-month high of $18.56.
周三,纽约证交所NVTA的股价开盘报2.57美元。该公司的50日移动均线价格为2.61美元,200日移动均线价格为2.93美元。该公司的负债权益比率为10.03,速动比率为6.18,流动比率为6.44。Invitae Co.的股价为1.83美元,为12个月低点,12个月高位为18.56美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several research analysts recently weighed in on the stock. StockNews.com raised shares of Invitae to a "sell" rating in a report on Friday, November 18th. William Blair reissued a "market perform" rating on shares of Invitae in a report on Tuesday, November 8th. Cowen downgraded shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 26th. Cowen increased their price objective on shares of Invitae to $2.80 in a report on Tuesday, November 15th. Finally, SVB Leerink increased their price objective on shares of Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a report on Wednesday, November 9th. Four analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $8.04.
几位研究分析师最近对该股进行了加码。在11月18日星期五的一份报告中,StockNews.com将Invitae的股票评级上调至“卖出”。威廉·布莱尔在11月8日星期二的一份报告中重新发布了对Invitae股票的“市场表现”评级。在7月26日周二的一份报告中,考恩将Invitae的股票评级从“跑赢大盘”下调至“市场表现”。考恩在11月15日星期二的一份报告中将Invitae的股票目标价上调至2.80美元。最后,SVB Leerink在11月9日(星期三)的一份报告中将Invitae的股票目标价从2.50美元上调至3.00美元,并给予该公司“市场表现”评级。四位分析师对该股的评级为卖出,九位分析师对该公司股票的评级为持有。根据MarketBeat的数据,该公司目前的共识评级为持有,共识目标价为8.04美元。
Invitae Company Profile
Invitae公司简介
(Get Rating)
(获取评级)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae公司是一家医学遗传学公司,将遗传信息整合到主流医学中,以改善美国、加拿大和国际上人们的医疗保健。该公司提供各种临床领域的基因测试,包括遗传癌、心脏病学、神经病学、儿科、肿瘤学、代谢疾病和罕见疾病;数字健康解决方案;以及健康数据服务。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- 免费获取StockNews.com关于Invitae的研究报告(NVTA)
- 在取消了13%的股息后,Lumen Technologies可以拥有吗?
- Dick‘s体育用品的卖方上限收益
- 思科希望重组削减成本以增加收入
- 想要获得10%的股息收益率,看看这里
- 炒股:3只有吸引力的股票,交易价格在10美元左右
Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invitae Co. (NYSE:NVTA – Get Rating).
想看看还有哪些对冲基金持有NVTA吗?访问HoldingsChannel.com获取Invitae Co.(纽约证券交易所代码:NVTA-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
接受《邀请日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Invitae和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。